FindTrial
Sign In

caprylic/capric triglyceride liquid

DRUG2 trials

Sponsors

Institut Gustave Roussy

Conditions

IIIII hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)Patients with stage I

Phase 3

Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint pain of adjuvant enDOcrine theRApy in patients with early breast cancer (PANDORA)
WithdrawnCTIS2023-505380-36-00
Institut Gustave RoussyII, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory), Patients with stage I
Target: 130Updated: 2024-01-15
Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint pain of adjuvant enDOcrine theRApy in patients with early breast cancer (PANDORA)
Not yet recruitingCTIS2023-505380-36-01
Institut Gustave RoussyII, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory), Patients with stage I
Target: 130Updated: 2025-08-06